Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance
Xiaowei Liu, Jinen Song, Hao Zhang, Xinyu Liu, Fengli Zuo, Yunuo Zhao, Yujie Zhao, Xiaomeng Yin, Xinyu Guo, Xi Wu, Hu Zhang, Jie Xu, Jianping Hu, Jing Jing, Xuelei Ma, Hubing Shi
Journal:CANCER CELL
IF:50.3
DOI:10.1016/j.ccell.2023.01.001
PMID:36706761
Published:2023-01-26
research field:肿瘤学诊疗一体化纳米医学生物成像光医学
Abstract
Circulating tumor cells (CTCs), shed by primary malignancies, function as "seeds" for distant metastasis. However, it is still largely unknown how CTCs escape immune surveillance. Here, we characterize the transcriptomes of human pancreatic ductal adenocarcinoma CTCs, primary, and metastatic lesions at single-cell scale. Cell-interaction analysis and functional studies in vitro and in vivo reveal that CTCs and natural killer (NK) cells interact via the immune checkpoint molecule pair HLA-E:CD94-NKG2A. Disruption of this interaction by blockade of NKG2A or knockdown of HLA-E expression enhances NK-mediated tumor cell killing in vitro and prevents tumor metastasis in vivo. Mechanistic studies indicate that platelet-derived RGS18 promotes the expression of HLA-E through AKT-GSK3β-CREB signaling, and overexpression of RGS18 facilitates pancreatic tumor hepatic metastasis. In conclusion, platelet-derived RGS18 protects CTCs from NK-mediated immune surveillance by engaging the immune checkpoint HLA-E:CD94-NKG2A. Interruption of the suppressive signaling prevents tumor metastasis in vivo by immune elimination of CTCs.
本文使用的Yeasen产品


